Clinical Trials Directory

Trials / Completed

CompletedNCT01472900

2940nm Er:YAG Laser Versus Benzoyl Peroxide Gel for the Treatment of Inflammatory Acne

A Randomized Split-Face Controlled Trial Comparing Efficacy of 2940 Nanometer Er:YAG Laser to 2.5% BP Gel for the Treatment of Inflammatory Acne

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
25 (estimated)
Sponsor
Chulalongkorn University · Academic / Other
Sex
All
Age
18 Years – 45 Years
Healthy volunteers
Not accepted

Summary

Acne is one of the most common conditions that patients seek for help in dermatological clinic. Nowadays, conventional treatment including topical agents(retinoids, antibiotics ,antiseptics and keratolytic agents) and systemic agents( antibiotics and retinoids) give a satisfying result but not to every patient. Some patients are not well respond to conventional therapy while some patients are unable to tolerate side effects of the treatments. Therefore, interventions to reduce acne are vigorously experimented . Lights and lasers including intense pulsed light, pulsed dye laser with or without photosensitizer and infrared lasers have been found to be useful in treating active inflammatory acne. Although,pain ,downtime and poor response of comedonal acne are limitations of those lights and lasers therapy. 2940 nm Erbium:YAG laser which has both resurfacing and photothermal effects is our laser of interest to seek for its efficacy in the treatment of inflammatory acne.

Conditions

Interventions

TypeNameDescription
DEVICE2940 nm Er:YAG laser (DualisXS M002-2A, Fotona®, Fotona d.d, Ljubljana, Slovenia)2 passes of 2940nm Er:YAG laser
DRUGBenzoyl Peroxide gel2.5% benzoyl peroxide gel apply twice daily on inflammatory acne on the control side of face

Timeline

Start date
2010-10-01
Primary completion
2012-04-01
Completion
2012-04-01
First posted
2011-11-17
Last updated
2012-06-19

Locations

1 site across 1 country: Thailand

Source: ClinicalTrials.gov record NCT01472900. Inclusion in this directory is not an endorsement.